


ABBREVIATED UNAUDITED ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2007
FOR
MOLECULAR RESEARCH LIMITED

TUESDAY



A34

A5S9MUF8

06/11/2007

4

COMPANIES HOUSE

MOLECULAR RESEARCH LIMITED

**CONTENTS OF THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 31 JANUARY 2007**

	Page
Abbreviated Balance Sheet	1
Notes to the Abbreviated Accounts	2

MOLECULAR RESEARCH LIMITED**ABBREVIATED BALANCE SHEET****31 JANUARY 2007**

		2007	2006
	Notes	£	£
FIXED ASSETS			
Tangible assets	2	1,138	945
CURRENT ASSETS			
Debtors		2,773	5,518
Cash at bank		13,790	8,302
		<u>16,563</u>	<u>13,820</u>
CREDITORS			
Amounts falling due within one year		<u>11,414</u>	<u>8,015</u>
NET CURRENT ASSETS		<u>5,149</u>	<u>5,805</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>6,287</u>	<u>6,750</u>
CAPITAL AND RESERVES			
Called up share capital	3	100	100
Profit and loss account		<u>6,187</u>	<u>6,650</u>
SHAREHOLDERS' FUNDS		<u>6,287</u>	<u>6,750</u>

The company is entitled to exemption from audit under Section 249A(1) of the Companies Act 1985 for the year ended 31 January 2007


The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2007 in accordance with Section 249B(2) of the Companies Act 1985

The director acknowledges his responsibilities for

- (a) ensuring that the company keeps accounting records which comply with Section 221 of the Companies Act 1985 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Section 226 and which otherwise comply with the requirements of the Companies Act 1985 relating to financial statements, so far as applicable to the company

These abbreviated accounts have been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies

The financial statements were approved by the director on 9 September 2007 and were signed by



D G Vallely - Director

The notes form part of these abbreviated accounts

MOLECULAR RESEARCH LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2007

1 ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention, in accordance with the Financial Reporting Standard for Smaller Entities (effective June 2002), and in accordance with applicable accounting standards

Accounting convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2005)

Turnover

Turnover represents net invoiced sales of services, excluding value added tax

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life

Fixtures & fittings 25% on cost

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date

2 TANGIBLE FIXED ASSETS

	Total £
COST	
At 1 February 2006	24,143
Additions	425
	<hr/>
At 31 January 2007	24,568
	<hr/>
DEPRECIATION	
At 1 February 2006	23,198
Charge for year	232
	<hr/>
At 31 January 2007	23,430
	<hr/>
NET BOOK VALUE	
At 31 January 2007	1,138
	<hr/>
At 31 January 2006	945
	<hr/>

MOLECULAR RESEARCH LIMITED

**NOTES TO THE ABBREVIATED ACCOUNTS - continued
FOR THE YEAR ENDED 31 JANUARY 2007**

3 CALLED UP SHARE CAPITAL

Authorised Number	Class	Nominal value	2007 £	2006 £
1,000	Ordinary	£1	<u>1,000</u>	<u>1,000</u>

Allotted, issued and fully paid Number	Class	Nominal value	2007 £	2006 £
100	Ordinary	£1	<u>100</u>	<u>100</u>

4 TRANSACTIONS WITH DIRECTOR

Dr D G Vallely provided the company with an interest free loan during the year which decreased by £528 to £4,597